Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection

References

• FajutraoLLocklearJPriaulxJA systematic review of the evidence of the burden of bipolar disorder in EuropeClin Pract Epidemiol Ment Health2009 2351319166608
   PubMedGoogle Scholar
• Sanchez-MorenoJMartinez-AranATabarés-SeisdedosRFunctioning and disability in bipolar disorder: An extensive reviewPsychother Psychosom20097828529719602917
   PubMed Web of Science ®Google Scholar
• KilbaneEJGokbayrakNSGalynkerIA review of panic and suicide in bipolar disorder: Does comorbidity increase riskJ Affect Disord20091151–211019000640
   PubMed Web of Science ®Google Scholar
• LingamRScottJTreatment non-adherence in affective disordersActa Psychiatr Scand2002105316417211939969
   PubMed Web of Science ®Google Scholar
• ScottJPopeMSelf-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalizationAm J Psychiatry2002159111927192912411230
   PubMed Web of Science ®Google Scholar
• KaneJMUtilization of long-acting antipsychotic medication in patient careCNS Spectr20061112 Suppl 1417 quiz 7–817146411
   PubMed Web of Science ®Google Scholar
• BondDJPratoomsriWYathamLNDepot antipsychotic medications in bipolar disorder: A review of the literatureActa Psychiatr Scand Suppl200743431617688458
   PubMedGoogle Scholar
• YathamLNAtypical antipsychotics for bipolar disorderPsychiatr Clin North Am200528232534715826735
   PubMed Web of Science ®Google Scholar
• TohenMVietaECalabreseJEfficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depressionArch Gen Psychiatry200360111079108814609883
   PubMed Web of Science ®Google Scholar
• WeislerRHCalabreseJRThaseMEEfficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: A post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studiesJ Clin Psychiatry200869576978218452345
   PubMed Web of Science ®Google Scholar
• KeckPEJrCalabreseJRMcIntyreRSAripiprazole monotherapy for maintenance therapy in bipolar I disorder: A 100-week, double-blind study versus placeboJ Clin Psychiatry200768101480149117960961
   PubMed Web of Science ®Google Scholar
• SuppesTVietaELiuSMaintenance treatment for patients with bipolar I disorder: Results from a North American study of quetiapine in combination with lithium or divalproex (trial 127)Am J Psychiatry2009166447648819289454
   PubMed Web of Science ®Google Scholar
• HirschfeldRMKeckPEJrKramerMRapid antimanic effect of risperidone monotherapy: A 3-week multicenter, double-blind, placebo-controlled trialAm J Psychiatry200416161057106515169694
   PubMed Web of Science ®Google Scholar
• KhannaSVietaELyonsBRisperidone in the treatment of acute mania: Double-blind, placebo-controlled studyBr J Psychiatry200518722923416135859
   PubMed Web of Science ®Google Scholar
• RendellJMGeddesJRRisperidone in long-term treatment for bipolar disorderCochrane Database Syst Rev20064CD00499917054229
   PubMed Web of Science ®Google Scholar
• SegalJBerkMBrookSRisperidone compared with both lithium and haloperidol in mania: A double-blind randomized controlled trialClin Neuropharmacol19982131761809617509
   PubMed Web of Science ®Google Scholar
• SmulevichABKhannaSEerdekensMAcute and continuation risperidone monotherapy in bipolar mania: A 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidolEur Neuropsychopharmacol2005151758415572276
   PubMed Web of Science ®Google Scholar
• SachsGSGrossmanFGhaemiSNCombination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: A double-blind, placebo-controlled comparison of efficacy and safetyAm J Psychiatry200215971146115412091192
   PubMed Web of Science ®Google Scholar
• YathamLNGrossmanFAugustynsIMood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trialBr J Psychiatry200318214114712562742
   PubMed Web of Science ®Google Scholar
• SheltonRCStahlSMRisperidone and paroxetine given singly and in combination for bipolar depressionJ Clin Psychiatry200465121715171915641878
   PubMed Web of Science ®Google Scholar
• NierenbergAAOstacherMJCalabreseJRTreatment-resistant bipolar depression: A STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidoneAm J Psychiatry2006163221021616449473
   PubMed Web of Science ®Google Scholar
• GoodwinGMEvidence-based guidelines for treating bipolar disorder: Revised second edition – recommendations from the British Association for PsychopharmacologyJ Psychopharmacol200923434638819329543
   PubMed Web of Science ®Google Scholar
• MalhiGSAdamsDLampeLClinical practice recommendations for bipolar disorderActa Psychiatr Scand Suppl2009439274619356155
   PubMedGoogle Scholar
• YathamLNKennedySHSchafferACanadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2009Bipolar Disord200911322525519419382
   PubMed Web of Science ®Google Scholar
• BowdenCLMyersJEGrossmanFRisperidone in combination with mood stabilizers: A 10-week continuation phase study in bipolar I disorderJ Clin Psychiatry200465570771415163260
   PubMed Web of Science ®Google Scholar
• VietaEGastoCColomFRole of risperidone in bipolar II: An open 6-month studyJ Affect Disord2001671–321321911869771
   PubMed Web of Science ®Google Scholar
• YathamLNBinderCKusumakarVRisperidone plus lithium versus risperidone plus valproate in acute and continuation treatment of maniaInt Clin Psychopharmacol200419210310915076019
   PubMed Web of Science ®Google Scholar
• YathamLNBinderCRiccardelliRRisperidone in acute and continuation treatment of maniaInt Clin Psychopharmacol200318422723512817157
   PubMed Web of Science ®Google Scholar
• VietaEBrugueEGoikoleaJMAcute and continuation risperidone monotherapy in maniaHum Psychopharmacol2004191414514716711
   PubMed Web of Science ®Google Scholar
• KnoxEDStimmelGLClinical review of a long-acting, injectable formulation of risperidoneClin Ther200426121994200215823763
   PubMed Web of Science ®Google Scholar
• McEvoyJPRisks versus benefits of different types of long-acting injectable antipsychoticsJ Clin Psychiatry200667Suppl 5151816822092
   PubMed Web of Science ®Google Scholar
• RainerMKRisperidone long-acting injection: A review of its long term safety and efficacyNeuropsychiatr Dis Treat20084591992719183782
   PubMedGoogle Scholar
• NesvagRHendsetMRefsumHSerum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medicationActa Psychiatr Scand20061141212616774657
   PubMed Web of Science ®Google Scholar
• KaneJMEerkedensMLindenmayerJPLong-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychoticAm J Psychiatry200316061125113212777271
   PubMed Web of Science ®Google Scholar
• KeithSUse of long-acting risperidone in psychiatric disorders: Focus on efficacy, safety and cost-effectivenessExpert Rev Neurother20099193119102665
   PubMed Web of Science ®Google Scholar
• HanCLeeMSPaeCUUsefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorderProg Neuropsychopharmacol Biol Psychiatry20073161219122317532106
   PubMed Web of Science ®Google Scholar
• QuirozJARisperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorderBiol Psychiatry2010312 [Epub ahead of print]
   Google Scholar
• SavasHAYumruMOzenMEUse of long-acting risperidone in the treatment of bipolar patientsJ Clin Psychopharmacol200626553053116974200
   PubMed Web of Science ®Google Scholar
• BenabarreACastroPSanchez-MorenoJ[Efficacy and safety of long-acting injectable risperidone in maintenance phase of bipolar and schizoaffective disorder]Actas Esp Psiquiatr2009373143147 Spanish.19533426
   PubMed Web of Science ®Google Scholar
• VietaENietoEAutetAA long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidoneWorld J Biol Psychiatry20089321922418609430
   PubMed Web of Science ®Google Scholar
• YathamLNFalluABinderCEA 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorderActa Psychiatr Scand Suppl2007434505617688463
   PubMedGoogle Scholar
• MalempatiRNBondDJYathamLNDepot risperidone in the outpatient management of bipolar disorder: A 2-year study of 10 patientsInt Clin Psychopharmacol2008232889418301123
   PubMed Web of Science ®Google Scholar
• MacfaddenWAlphsLHaskinsJTA randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequentlyBipolar Disord200911882783919922552
   PubMed Web of Science ®Google Scholar
• El-MallakhRSMedication adherence and the use of long-acting antipsychotics in bipolar disorderJ Psychiatr Pract2007132798517414683
   PubMedGoogle Scholar
• LlorcaPMPartial compliance in schizophrenia and the impact on patient outcomesPsychiatry Res2008161223524718849080
   PubMed Web of Science ®Google Scholar
• CalabreseJRVietaEEl-MallakhRMood state at study entry as predictor of the polarity of relapse in bipolar disorderBiol Psychiatry2004561295796315601606
   PubMed Web of Science ®Google Scholar
• LittlejohnRLeslieFCooksonJDepot antipsychotics in the prophylaxis of bipolar affective disorderBr J Psychiatry199416568278297881787
   PubMed Web of Science ®Google Scholar
• SimpsonGMMahmoudRALasserRAA 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorderJ Clin Psychiatry20066781194120316965196
   PubMed Web of Science ®Google Scholar
• FleischhackerWWEerdekensMKarcherKTreatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychoticJ Clin Psychiatry200364101250125714658976
   PubMed Web of Science ®Google Scholar
• ChuePEerdekensMAugustynsIComparative efficacy and safety of long-acting risperidone and risperidone oral tabletsEur Neuropsychopharmacol200515111111715572280
   PubMed Web of Science ®Google Scholar
• LeuchtSKomossaKRummel-KlugeCA meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophreniaAm J Psychiatry2009166215216319015230
   PubMed Web of Science ®Google Scholar
• LeuchtSCorvesCArbterDSecond generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysisLancet20093739657314119058842
   PubMed Web of Science ®Google Scholar
• HamannJMendelRHeresSHow much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?Eur Neuropsychopharmacol201020427627920133108
   PubMed Web of Science ®Google Scholar
• JaegerMRosslerWAttitudes towards long-acting depot antipsychotics: A survey of patients, relatives and psychiatristsPsychiatry Res20101751–2586220004980
   PubMed Web of Science ®Google Scholar
• LindenmayerJPJarboeKBossieCAMinimal injection site pain and high patient satisfaction during treatment with long-acting risperidoneInt Clin Psychopharmacol200520421322115933482
   PubMed Web of Science ®Google Scholar